Benjamin Levy, MD, considers the realignment of treatments for non–small cell lung cancer (NSCLC) in which established therapies in the advanced setting are now being applied in early-stage disease, prompting a new concern for proper regimen sequencing in order to improve patient outcomes.
Dr Levy points to signs of even greater innovations on the horizon, such as CAR T-cell therapy, which together with other immune therapies promise to bring fully realized personalized care for patients with lung cancer into the clinical mainstream.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Treatment of Advanced and Metastatic NSCLC: Getting From the Good to the Best - Medscape - Sep 28, 2022.